• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Recurrence of Group B Streptococcal infection similar in shortened and prolonged therapy

byMatthew Lin, MDandCordelia Ross
October 11, 2018
in Infectious Disease, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

The rates of Group B Streptococcal (GBS) bacteremia recurrence in infants with an initial course of late-onset infection who received shortened and prolonged IV antibiotic therapy were 1.8% and 2.3%, respectively. There was no significant difference in the adjusted absolute difference between these 2 rates.

Evidence Rating Level: 2 (Good)

Study Rundown: GBS is the most common bacterial infection in infants, with no significant change in rates of late onset GBS infection (occurring at 7 to 90 days of age). Current guidelines published by the Committee on Infectious Diseases recommend prolonged IV antibiotic therapy (10 days) for uncomplicated GBS bacteremia. The purpose of this study was to compare rates of failure in subjects with late onset GBS who received prolonged (10 days) or shortened (≤8 days) antibiotic therapy. The primary outcome, recurrent GBS infection (defined as hospital revisit with a discharge diagnosis of GBS bacteremia, meningitis, or osteomyelitis within the first year of life) occurred at low rates in both the prolonged and shortened IV therapy groups, with no significant differences between the rates. Treatment failure (defined as recurrence of GBS disease 14 days from hospital discharge) similarly occurred at low rates in both groups, without significant differences between rates. The study was limited by reliance on medical coding, although validating testing was performed, and lack of data on possible use of outpatient antibiotics following admission. These data suggest that shortened IV therapy may be a reasonable alternative to prolonged IV therapy in GBS infection, preventing prolonged hospital stays and iatrogenic infections.

Click to read the study, published today in Pediatrics

Relevant Reading: Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis

In-Depth [retrospective cohort]: Subjects were identified through the Pediatric Health Information System Database (PHIS), a comparative pediatric database consisting of 49 children’s hospitals in the United States. Inclusion criteria included age ≤4 months and discharge from a PHIS center between January 2000 and September 2015 with an ICD-9 discharge code of GBS disease or bacteremia. Subjects were excluded for age <7 days, ICD-9 codes for an invasive bacterial or viral infection, a concomitant non-GBS bacterial infection, prematurity <29 weeks’ gestational age (GA), birth weight (BW) <1500g or a severe hospital course requiring intensive care. Out of 1369 infants ≤4 months of age with GBS bacteremia, 775 were included in the final analysis; of these, 612 (79%) received prolonged IV therapy and 163 (21%) received shortened IV therapy. The sensitivity for ICD-9 coding in detecting GBS bacteremia (confirmed with culture) was 72% and the PPV was 96%. The most common antibiotics prescribed were ampicillin and third-generation cephalosporins (37%), followed by cephalosporin monotherapy (28%) and a third-generation cephalosporin and vancomycin (7%). There were 17 (2.2%) patients who developed the primary outcome of GBS recurrence: 3 (1.8%) in the shortened IV therapy group and 14 (2.3%) in the prolonged IV therapy group (adjusted absolute difference = -0.2%, 95% CI = -3.0%-2.5%).Treatment failure in the shortened and prolonged IV therapy groups occurred in 1 (0.5%) and 6 (1%) subjects, respectively (adjusted absolute difference  = -0.3%, 95% CI = -1.8%-1.1%).

Image: CC

RELATED REPORTS

2 Minute Medicine Rewind January 23, 2023

High emergency department pediatric readiness associated with decreased mortality

Intimate partner violence associated with poor socioemotional development in children

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bacteremiabacterial infectionGBSpediatric infectious diseasespediatricssepsis
Previous Post

Polymyxin B hemoperfusion unlikely to reduce mortality for sepsis

Next Post

Quick Take: Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomized, placebo-controlled trial 

RelatedReports

Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Weekly Rewinds

2 Minute Medicine Rewind January 23, 2023

January 30, 2023
Quick Take: Impact of scribes on emergency medicine doctors’ productivity and patient throughput: multicentre randomised trial
Emergency

High emergency department pediatric readiness associated with decreased mortality

January 16, 2023
Meeting families, demographic information affect child abuse work-up
Pediatrics

Intimate partner violence associated with poor socioemotional development in children

January 5, 2023
Hypotonic IVF linked to increased risk of hyponatremia
Emergency

Balanced intravenous solutions reduce risk of hyperchloremia in the pediatric intensive care unit

January 5, 2023
Next Post

Quick Take: Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomized, placebo-controlled trial 

Food environment associated with gestational diabetes

Quick Take: Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Quick Take: Single-dose versus 7-day-dose metronidazole (Flagyl) for the treatment of trichomoniasis in women: an open-label, randomized controlled trial

Quick Take: Single-dose versus 7-day-dose metronidazole (Flagyl) for the treatment of trichomoniasis in women: an open-label, randomized controlled trial

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
  • Homicide deaths are on the rise for children living in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options